The wedding is still a few months away, but Merck's
It doesn't look as if Merck is letting Schering-Plough
But even though the new Merck will look a lot like the old Merck at the top, Merck did say that about 40% of Schering's "senior leaders" will be headed to the new company.
The intertwined nature of the pharmaceutical industry has made this merger as complex as a polygamists' divorce. The acquisition of Schering would allow Johnson & Johnson
Merck also had problems with its partners. After the merger, it was going to be in an awkward position of having two competing animal-health divisions: its joint venture with sanofi-aventis
Meanwhile, even though the wedding details are almost complete, investors may have to wait awhile to know whether the purchase was a good investment for Merck. Unlike the Pfizer
Johnson & Johnson is an Income Investor recommendation. To see how dividend-paying stocks can offer both secure income and the opportunity for growth, take a free look at this newsletter service with a 30-day free trial.